Hormone Replacement Therapy (HRT) Market

SKU: DMPH2744 | Last Updated On: Oct 01 2022 | Available Formats

>Hormone Replacement Therapy (HRT) Market Expected to reach a high CAGR of 5.1% during the forecast period 2022-2029: DataM Intelligence

Hormone Replacement Therapy (HRT) Market is segmented By Product (Thyroid Hormone Replacement Therapy, Estrogen Hormone Replacement Therapy, Testosterone Hormone Replacement Therapy, Human Growth Hormone Replacement Therapy, Human Growth Hormone Replacement Therapy), By Route of Administration (Oral, Parenteral, Transdermal, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Drugstores, Online Pharmacy, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

 

[150 Pages Report] The Hormone Replacement Therapy (HRT) market was valued at USD 14,553.5 million in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of 5.1% during the forecast period (2022-2029).

Hormone Replacement Therapy (HRT) Market Report Scope:

Metrics

Details

CAGR

5.1%

Segments Covered

By Product Type, By Route of Administration, By Distributional Channels, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Regions Analyzed

North America, Latin America, Europe, Middle East, Africa, Asia Pacific, and the Rest of the world.

Major Companies Covered

Abbott Laboratories, EKF Diagnostics Holdings plc, BioMérieux SA, Atlas Medical, Quidel Corporation, BIOSYNEX SA, Prestige Brands Holdings, Swiss Precision Diagnostics (SPD) GmbH, Piramal Enterprises, NG BIOTECH SAS, and among the major companies listed in the final report.

To know more insights into the Diagnostic Imaging Market, get our Sample Brochure

Hormone replacement therapy (HRT) is a technique for replacing and replenishing hormones in the human body, which are at inadequate levels than those required for the normal physiology of the human body. Hormone replacement therapy helps to balance the estrogen and progesterone levels during or near menopause. During menopause, hormonal therapy or menopausal hormone therapy, hormone replacement therapy helps to relieve hot flashes, sweating, and other symptoms of menopause. HR therapy has also been proved to prevent bone loss and reduce fracture in postmenopausal women. Systemic hormone therapy which comes in pill, cream, spray form, skin patch, or gel is one of the most effective treatments for the relief of menopausal hot flashes and night sweats.

Market Dynamics

The hormone replacement therapy market growth is driven by some of the major factors such as growing awareness of post-menopausal issues among women, increasing drug development with novel delivery systems, and hormonal imbalance disorders with the growing geriatric population.

Rising hormonal imbalance disorders with a growing geriatric population drive the HRT market growth

Hormonal imbalance disorders, with a growing geriatric population, is one of the major factors driving the growth of the HRT market. With several hormonal changes, the female body predominantly gets affected by the natural process of aging, which leads to abnormalities and diseases. Some of the common problems include fatigue, weight gain, memory decline, low libido, aging appearance, and muscle loss.

The most frequent consequence of age-related hormonal changes occurs in cases related to menopause. The global average onset age for menopause among women is approximately 50 years. In women, the production levels of estrogen and progesterone decrease significantly by the age of 50 years and above. This decrease in production levels of estrogen and progesterone is compensated by the pituitary gland, with the increased production of follicle-stimulating hormone (FSH). This is physically manifested in women in the form of post-menopause symptoms, which include flush.

Increasing Development in the Hormone Replacement Therapy

The hormone replacement therapy market has observed significant development over the past few years and is expected to grow significantly during the forecast period. With the increasing frequencies of hormonal lopsidedness issues and expanding age and the neonatal populace, these sicknesses are foreseen to advance development.  The rising interest in hormone replacement therapy is driven by the existence of routinely observed details, growing technological progression in the field of drug delivery frameworks, and rising awareness among patients. Menopausal females frame the biggest segment influencing the market and subsequently, the rising female populace between the age gathering of 45 to 59 and expanding the scope of the menopausal window are anticipated to push development.

In January 2020, a new menopause health service has launched in California that offers women remote consultations and, for the first time, mail-order prescriptions of menopause hormone replacement therapies. The telemedicine platform, called CurieMD, offers consumers video consultation with a board-certified midlife health practitioner (free at launch, and $39 for follow-up appointments). The FDA-approved bio-identical hormone treatments on offer come as oral tablets, vaginal creams, and oral contraceptive pills, and are offered as quarterly payment plans.

Side effects and risks associated with HRT might hamper the market growth

Hormone Replacement Therapy has several side effects such as indigestion, depression, fluid retention, headache, among others. These side effects are anticipated to hamper the adoption of this therapy.

Hormone replacement therapy might cause some risks for people with uncontrolled hypertension, or high blood pressure, thrombosis or blood clots, high levels of triglycerides in the blood, stroke, heart disease, breast cancer, and gallbladder disease.

Also, according to a UK-based NICE finding, hormone replacement therapy is associated with breast cancer risk if the drugs progesterone and oestrogen are taken in combination. Prolonged consumption of HRT drugs might lead to an increased risk of blood clots also. Every 1,000 women taking HRT tablets for 7.5 years, less than two will develop a blood clot, as per some studies.

Epidemiology

Hypothyroidism:

According to the National Health and Nutrition Examination Survey (NHANES 1999-2002), of 4392 individuals reflecting the US population reported hypothyroidism (defined as TSH levels exceeding 4.5 mIU/L) in 3.7% of the population. Hypothyroidism is most common in women with small body size at birth and low body mass index during childhood.

Iodine deficiency as a cause of hypothyroidism is more common in less-developed countries. Routine supplementation of salt, flour, and other food staples with iodine has decreased the rates of iodine deficiency.

The World Health Organization (WHO) data from 130 countries taken from January 1994 through December 2006 found inadequate iodine nutrition in 30.6% of the population. The WHO recommends urinary iodine concentrations between 100 and 199 μg/L in the general population and a range of 150-249 μg/L in pregnant women.

The frequency of hypothyroidism, goiters, and thyroid nodules increases with age. Hypothyroidism is most prevalent in elderly populations, with 2-20% of older age groups having some form of hypothyroidism. The Framingham study found hypothyroidism (TSH > 10 mIU/L) in 5.9% of women and 2.4% of men older than 60 years. In NHANES 1999-2002, the odds of having hypothyroidism were five times greater in persons aged 80 years and older than in individuals aged 12-49 years.

The NHANES 1999-2002 reported that the prevalence of hypothyroidism was higher in whites (5.1%) and Mexican Americans than in African Americans (1.7%). The African Americans tend to have lower median TSH values.

Market Segmentation

The global hormone replacement therapy (HRT) market is segmented based on the product, disease type, route of administration, and distribution channel.

Based on Disease, Menopause is Expected to Growth at High CAGR over the Forecast Period

Menopause is the stage that marks the end of the menstrual cycle. It is diagnosed after 12 months without a menstrual period. Menopause can happen at the age of 40 or 50. Menopause is a natural biological process. Hormone replacement therapy improves the quality of life and prolongs life for elderly women, whether it is initiated at menopause or much later. The therapy helps elderly women maintain their estrogen levels.

The menopause segment growth is expected to increase as the geriatric population globally increases. The United Nations has estimated that 980 million women globally in 2020 are aged 50 and over. This figure can be further estimated to rise to 1.65 billion by 2050. In 2020, the number of United States women aged older than 51 years was expected to be more than 50 million. This change is expected to be more prevalent in developed countries. Hence, as both men and women age, the application of HRT in older women is expected to grow, which will help the market growth.

As per the American Congress of Obstetricians and Gynecologists, about 6,000 women reach menopause daily. The presence of several branded and generic drugs and growing awareness among women are expected to be the vital impact of rendering drivers.

By Product, Estrogen Segment is Expected to Hold Largest Market Share During the Forecast Period

Based on product, the HRT market is segmented into therapies for estrogen, testosterone, human growth hormone, and thyroid hormones. Among these, the estrogen hormone replacement therapy segment accounted for the largest market share in 2021, as estrogen-based products have been studied to generate the largest number of prescriptions. Estrogen replacement therapy is used in women during post-menopause or hysterectomy, which helps them to maintain the hormonal balance.

On the other hand, the human growth hormone therapy is expected to grow at the fastest CAGR over the forecast period due to the increasing incidences of growth deficiencies, especially in infants. For instance, as per a survey organized by the WHO, around 15 million newborns are born premature, and around 85% of these infants are not fully developed. In adults, hormone therapy is provided for conditions such as short bowel syndrome and pituitary tumors.

Geographical Presentation

North America region holds the largest market share in the global Hormone Replacement Therapy market

North America region is dominating the global hormone replacement therapy market accounted for the largest market share in 2021, owing to the growing geriatric population in the United States and Canada. As per the National Institutes of Health (NIH), almost half of all the post-menopausal women in the United States reported having used hormone replacement therapy at least once in their life. The conjugated equine estrogens (CEE)/bazedoxifene tablet, a combination of estrogen and a selective estrogen receptor modulator, is available in the U.S. for menopausal VMS treatment and osteoporosis prevention. Overall, the market for hormone replacement therapy in the United States is scheduled for high growth over the forecast period, due to the growing adoption of hormone replacement therapy among women, for both post-menopausal and menopause management.

The Asia Pacific is the fastest-growing market in the global hormone replacement therapy market

The Asia Pacific HRT market is expected to witness the fastest growth over the forecast period from 2022 to 2029. Increasing awareness levels and the rising focus of healthcare providers on the eradication of hormonal deficiencies are expected to boost the growth of the market within the region.

Competitive Landscape:

The hormone replacement therapy market is consolidated and competitive. Some of the key players which are contributing to the growth of the market include Abbott Laboratories, Pfizer, Inc., Bayer AG, Novartis AG, Allergan Plc, Novo Nordisk A/S, Mylan NV, F. Hoffmann-La Roche, Eli Lilly, and Company, among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the hormone replacement therapy market globally. For instance, on 23rd November 2019, Theramex acquired global rights to Janssen’s Evorel patches. This acquisition aims needs to be aware of the supply chain of HRT shortages and is dedicated to resolving this issue.

Abbott Laboratories

Overview:

Abbott Laboratories headquarters in the United States is a global medical device and health care company. The company has four business segments: medical devices, diagnostics, branded generic medicines, and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013. In March 2020, Abbott received emergency use authorization (EUA) from the FDA for a 2019-nCoV test to help mitigate the COVID-19 pandemic.

COVID-19 Impact Analysis

The COVID-19 is affecting the global economy by directly affecting production and demand, by disturbing the supply chain and market disruption, and by its financial impact on firms and financial markets. The global hormone replacement therapy (HRT) market has been impacted by the COVID-19 pandemic, as stakeholders are increasingly searching for newer approaches towards diagnosing and curing patients affected by the COVID-19.

Exogenous estrogen and testosterone therapies have a therapeutic potential to mitigate the damaging inflammatory response to SARS-CoV-2 without hampering the immune system’s response to the virus as corticosteroids do. The use of immune-modulating drugs to block inflammatory markers’ receptors to mitigate the amplified and tissue-damaging immune response of SARS-CoV-2 (eg, anarka [an IL-1 receptor blocker] and tocilizumab and sarilumab [IL-6 receptor antagonists]). However, there are concerns about these agents’ possible adverse effects on the patient's immune function.

According to research from King's College London, the University of Liverpool, and Zoe Global Limited, aimed at contributing to an evaluation of the potential for estrogen treatment in COVID-19, by examining the presence of an association between high estrogen levels and lower levels of COVID-19 infection and severity in women.

The researchers showed that the rate of predicted COVID-19 was higher in postmenopausal women on HRT, who also showed a higher frequency of related symptoms but not of hospitalization. HRT use was associated with a trend towards lower respiratory support and positive testing. The age-group analysis showed the effects to be highest in the 55–60-year age group.

The researchers also looked at the effect of exogenous estrogen in the form of the combined oral contraceptive pill (COCP) on COVID-19-related symptoms and infection, and the effect of hormone replacement therapy (HRT) on COVID-19 positivity and symptom severity in women past menopause.

There is a need for future research to examine whether hormone replacement therapy may have a pharmacotherapeutic role in treating older adults diagnosed with COVID-19.

Trending Topics

Growth Hormone Deficiency Market

Pheromones Market

FAQ

What is the Hormone Replacement Therapy (HRT) Market growth?

The market is growing at a CAGR of 5.1%.

What is Hormone Replacement Therapy (HRT) Market size in 2021

The Hormone Replacement Therapy (HRT) Market size was valued at USD YY million in 2021.

Who are the key players in Hormone Replacement Therapy (HRT) Market?

Bayer AG, Novartis AG, Allergan Plc, Novo Nordisk A/S, Mylan NV, F. Hoffmann-La Roche, Eli Lilly.

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest